Pall Biotech to focus on enabling drug manufacturers to rapidly transition from pre-clinical to commercial manufacturing.
Pall Corporation has a newly named business unit within the Pall Life Sciences division. The Pall Biotech business unit has been named to reflect an important strategic direction for the company. The update will not impact current or prospective company operations.
“As the lines between the biopharmaceutical and biotechnology sectors continue to merge, our commitment is stronger than ever to develop and deliver end-to-end capabilities with cutting-edge technologies and services. The name Pall Biotech reflects a more focused approach to serving these high-growth market segments,” said Mario Philips, Vice President & General Manager of Pall Biotech. “It also reflects our dedication to reducing costs, while increasing efficiency and quality, for today’s developer of sensitive biologic products, including mAbs, recombinant proteins, viral vaccines, and cell and gene therapies.”
Critical partnerships in the industry and alignment with regulatory agencies will play a key role in improving both the integrated and stand-alone elements of the Pall Biotech total bioprocessing solutions portfolio.
“Pall Biotech does not make drugs—we enable drug manufacturers with rapid transition from pre-clinical to commercial manufacturing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In 2018, our Pall Life Sciences division boasts the most complete solutions from drug discovery through delivery with Pall Laboratory for research and discovery, Pall Biotech enabling next-generation manufacturing processes, and Pall Medical for patient delivery.”Read More
The log-in process has been changed. If you have trouble logging into your company profile please click here.